Publicly traded Canadian biotech company developing first-in-class small molecules focused on epigenetics targets to treat cardiovascular disease.
Destum Partners leveraged several resources to achieve our clients goals:
• Primary Market Research: KOLs and payers were interviewed to determine the unmet medical need, the gap fill based on the TPP, potential use and drug pricing with reimbursement considerations
• Internal Expertise: Several consulting projects completed in the cardiovascular field
Summary and Results
Several primary market research studies have been completed for our Client testing their target product profile with a variety of physician types including cardiologist, endocrinologist, nephrologists and Neurologists. Payor primary and secondary market research studies have been completed to determine the core cost benefit drivers and a price range with a high likelihood of reimbursement.
Destum Partners used the result of the market research studies to build a business case and determine the asset potential for our client, based on indication, and prescriber group. In addition, the primary market research studies informed strategic development considerations from a patient stratification perspective and clinical end-point perspective. A commercial strategy was developed for the various indications evaluated and covered relevant material from commercial infrastructure, positioning, and marketing strategy and tactics.
The outputs of asset potential, product development and commercial strategy were used by our Client to help secure USD 50M in funding for further development of their drug.